Candidoza generalizată la o pacientă postcovid 19 - diagnosticul diferențiat
Cuvinte cheie:
COVID-19, candidozăRezumat
S-a descris cazul clinic al unei paciente de 74 de ani cu pancitopenie severă, apărută după o infecție suportată cu SARS-CoV2. Cazul dat prezintă interes prin dificultatea stabilirii diagnosticului și severitatea evoluției bolii. Pancitopenia a apărut în timpul suportării de COVID-19 și a progresat în perioada postCOVID-19 pe parcursul a circa 3 luni, cu agravarea stării generale a pacientei, dezvoltarea candidemiei generalizate și deces, în pofida tratamentului administrat. Prezintă interes dificultatea stabilirii diagnosticului în perioada postCOVID-19. Candidoza, o infecție fungică oportunistă, a devenit mai răspândită pe măsură ce lumea continuă să lupte împotriva COVID-19. Este crucial să înțelegem patogeneza și mecanismul virulenței pentru a face lumină asupra progresiei bolii, în special în cazul co-infectiilor. diferiții factori, care predispun pacienții cu COVID-19 la candidoză, interacțiunile lor și efectele individuale trebuie bine înțeleși pentru a preveni dezvoltarea co-infecțiilor oportuniste, care scad drastic șansele de supraviețuire ale pacienților.
Referințe
1. Hernandez, JM. et al. Pancytopenia and profound neutropenia as a sequela of severe SARS-CoV-2 infection (COVID-19) with concern for bone marrow involvement. In: Open Forum Infectious Diseases: 2021: Oxford University Press US; 2021: ofab017. https://doi.org/10.1093/ofid/ofab017
2. Salgado, R.C. et al. The network interplay of interferon and Toll-like receptor signaling pathways in the antiCandida immune response. Sci. Rep. 2021, 11, 20281. https://doi.org/10.21203/rs.3.rs-279551/v1
3. Baddley, J.W. et al. Coronavirus Disease 2019-Associated Invasive Fungal Infection. Open Forum Infect. Dis. 2021, 8, ofab510. https://doi.org/10.1093/ofid/ofab510
4. Gangneux, J.P. et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study. Lancet Respir. Med. 2022, 10, 180-190.
5. Kayaaslan, B. et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to nonCOVID-19 patients. Mycoses 2021, 64, 1083-1091. https://doi.org/10.1111/myc.13332
6. Machado, M. et al. Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission. J. Fungi 2022, 8, 305. https://doi.org/10.3390/jof8030305
7. Mastrangelo, A. et al. Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021, 73, e2838-e2839. https://doi.org/10.1093/cid/ciaa1594
8. Pfaller, MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133-163. https://doi.org/10.1128/CMR.00029-06
9. Oliva, A. et al. Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19. Front. Immunol. 2021, 12, 708149. https://doi.org/10.3389/fimmu.2021.708149
10. Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 2021, 6, eabl4340.
11. Terpos E. et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47. https://doi.org/10.1002/ajh.25829
12. Wang F, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI insight. 2020; 5(10). https://doi.org/10.1172/jci.insight.137799
13. Weiskopf D. et al. Phenotype and kinetics of SARSCoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. https://doi.org/10.1126/sciimmunol.abd2071
14. Wang F. et al. Systemically comparing host immunity between survived and deceased COVID-19 patients. Cell Mol Immunol. 2020;17(8):875-7. https://doi.org/10.1038/s41423-020-0483-y
15. Sharma C. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17(12):731-48. https://doi.org/10.1038/s41584-021-00709-9
16. Martinez OM. et al. The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. Nat Med. 2020;26(12):1819-24. https://doi.org/10.1038/s41591-020-1140-9
17. Pascutti MF. et al. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Front Immunol. 2016;7:364. https://doi.org/10.3389/fimmu.2016.00364
18. Brisse E. et al. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263-80. https://doi.org/10.1016/j.cytogfr.2014.10.001
Publicat
Număr
Secțiune
Licență
Această lucrare este licențiată în temeiul Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
